AcquisitionsApr 8, 2026, 09:06 AM
Drugs Made In America Acquisition Corp. (DMAA) Enters LOI for $1.0 Billion De-SPAC Transaction with Power Analytics Global Corp.
AI Summary
Drugs Made In America Acquisition Corp. (DMAA) announced on April 7, 2026, that it has entered into a Letter of Intent (LOI) with Power Analytics Global Corp., a Delaware corporation, for a de-SPAC transaction. This agreement aims to bring Power Analytics Global Corp. public through a business combination with DMAA. The anticipated valuation for the target company is approximately $1.0 billion, although this figure is subject to further negotiation, due diligence, and adjustments based on various financial factors and market conditions. This LOI marks a significant step for DMAA in fulfilling its mandate to identify and merge with a suitable operating business, signaling progress towards its ultimate goal.
Key Highlights
- Drugs Made In America Acquisition Corp. (DMAA) entered into a Letter of Intent (LOI) on April 7, 2026.
- The LOI is with Power Analytics Global Corp., a Delaware corporation, for a de-SPAC transaction.
- The transaction is anticipated to result in Power Analytics Global Corp. becoming a public company.
- The target company, Power Analytics Global Corp., is expected to have an approximate valuation of $1.0 billion.
- The final terms and valuation are subject to further negotiation, execution of a definitive business combination agreement, due diligence, capital structure, net debt, working capital, and market conditions.